Premium
Type‐I Interferon assessment in 45 minutes using the FilmArray ® PCR platform in SARS‐CoV‐2 and other viral infections
Author(s) -
Mommert Marine,
Perret Magali,
Hockin Matthew,
Viel Sébastien,
Belot Alexandre,
Richard JeanChristophe,
Mezidi Mehdi,
Fassier JeanBaptiste,
Javouhey Etienne,
Hemmert Andrew,
Mallet François,
TrouilletAssant Sophie,
BrengelPesce Karen
Publication year - 2021
Publication title -
european journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.272
H-Index - 201
eISSN - 1521-4141
pISSN - 0014-2980
DOI - 10.1002/eji.202048978
Subject(s) - interferon , covid-19 , virology , pandemic , disease , medicine , biology , immunology , infectious disease (medical specialty)
Abstract Low concentrations of type‐I interferon (IFN) in blood seem to be associated with more severe forms of Coronavirus disease 2019 (COVID‐19). However, following the type‐I interferon response (IR) in early stage disease is a major challenge. We evaluated detection of a molecular interferon signature on a FilmArray® system, which includes PCR assays for four interferon stimulated genes. We analyzed three types of patient populations: (i) children admitted to a pediatric emergency unit for fever and suspected infection, (ii) ICU‐admitted patients with severe COVID‐19, and (iii) healthcare workers with mild COVID‐19. The results were compared to the reference tools, that is, molecular signature assessed with Nanostring® and IFN‐α2 quantification by SIMOA® (Single MOlecule Array). A strong correlation was observed between the IR measured by the FilmArray®, Nanostring®, and SIMOA® platforms (r‐Spearman 0.996 and 0.838, respectively). The FilmArray® panel could be used in the COVID‐19 pandemic to evaluate the IR in 45‐min with 2 min hand‐on‐time at hospitalization and to monitor the IR in future clinical trials.